Systemic Lupus Erythematosus (Immunotherapy)

Peptides Prevent Experimental SLE in Mice

Published in Gene Therapy Weekly, May 12th, 1997

Depending on how they were administered, two novel peptides either caused or prevented systemic lupus erythematosus (SLE) in mice.

The peptides are based on the complementarity-determining regions (CDRs) of a murine monoclonal antibody (mAb 5G12) that induces SLE in various strains of naive mice.

"The CDR-based peptides are potential candidates for therapy of SLE," reported Ari Waisman and colleagues of The Weizmann Institute of Science, Rehovot 76100, Israel ("Modulation of Murine Systemic Lupus Erythematosus with Peptides Based on Complementarity Determining Regions of a Pathogenic Anti-DNA Monoclonal Antibody," PNAS, 1997;94:4620-5).

...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Gene Therapy Weekly

Source: Gene Therapy Weekly (1997-05-12)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry